RAC - Charts & Price Action, page-18226

I hope it does, there are a few ASX listed bios sitting on RPDDs.

I guess I still don't understand why, after being awarded RPDD back in July 2018, Race didn't immediately design 1 or 2 Paediatric AML trials with guidance from the FDA to get approval. Surely 50 previous clinical trials worth of safety and efficacy data would have made that relatively easy to do?

Imagine that, Race could be close to FDA approval in Paediatric AML by now, providing ongoing revenue and $50-100m from the sale of a PRV!

That would provide funding for RC220 with some leftover for shareholders.

Or is all that data from 50 clinical trials not very compelling? That's a tonne of trials!

Anyway, I continue to watch with interest (and some confusion). CP is why I'm still interested and probably why many more recent investors are here.